CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

But Biokin Hot On Heels With Bispecific

 
• By Xu Hu
  
Two assets are ready to compete
CSPC's EGFR-targeting ADC SYS6010 showed favorable efficacy in Phase I, especially in patients with EGFR-mutant NSCLC who were resistant to previous EGFR-TKI treatments. (Shutterstock)

More from China

More from Therapy Areas